Research

Our Clinical Research Experience

Since founding Pure Ophthalmic Research in 2021, Dr. Aynsley Girardeau and her research team have participated in multiple clinical trials investigating innovative treatments for ocular diseases.

Our research experience includes Phase 2 and Phase 3 clinical trials conducted in collaboration with pharmaceutical companies, focusing on dry eye disease, childhood myopia, and Demodex blepharitis.

Clinical Trials and Research Partners

Palatin Technologies, Inc.

• Phase 3 clinical trial evaluating PL9643 ophthalmic solution for dry eye disease.

Ocumension (Hong Kong) Limited

• Phase 3 clinical trial investigating low-dose atropine (0.01%) for slowing the progression of childhood myopia.

Aerie Pharmaceuticals

• COMET-3 Phase 3 clinical trial evaluating AR-15512 for the treatment of dry eye disease.

• This treatment subsequently received FDA approval as TRYPTYR in May 2025.

Aldeyra Therapeutics, Inc.

• TRANQUILITY and TRANQUILITY-2 clinical trials investigating reproxalap ophthalmic solution for dry eye disease.

​​​​​​​Tarsus Pharmaceuticals, Inc.

• SATURN-2 Phase 3 clinical trial evaluating TP-03 for the treatment of Demodex blepharitis.

• This treatment subsequently received FDA approval as XDEMVY in July 2023.

Contributing to Advancements in Eye Care

We are proud to have participated in clinical research programs that contributed to the development of two FDA-approved ophthalmic treatments: XDEMVY and TRYPTYR.

Through Pure Ophthalmic Research, we remain committed to advancing the understanding and treatment of eye disease while maintaining the highest standards of patient care and clinical research.